CONcurrent ChEmotherapy and RadioTherapy in adjuvant treatment of breast cancer (CONCERT): a phase 2 study.
Tabassum Wadasadawala, Akanksha Anup, Johnny Carlton...
https://pubmed.ncbi.nlm.nih.gov/37113709/Actively Recruiting
Led by Dr. Tabassum Wadasadawala · Updated on 2025-04-13
858
Participants Needed
5
Research Sites
N/A
Total Duration
Researchers are evaluating whether giving chemotherapy and radiation therapy at the same time concurrent is more effective than giving them one after the other sequential for patients with stage IIB-III invasive breast cancer. The study aims to find out if concurrent treatment improves disease-free survival, affects quality of life and side effects like arm swelling, and how the costs compare between these approaches. This is a Phase III randomized controlled trial sponsored by Dr. Tabassum Wadasadawala. Participants will be randomly assigned to one of two groups. One group will receive chemotherapy first, followed by radiation therapy sequential treatment. The other group will receive chemotherapy and radiation therapy at the same time concurrent treatment. Chemotherapy typically includes taxanes andor anthracyclines, and radiation therapy will be given for three to four weeks. Both groups will follow these treatment schedules as part of their adjuvant therapy after surgery. During the study, participants will have follow-up visits every six months for five years to monitor cancer recurrence, side effects, and quality of life. Assessments will include disease-free survival over three years, quality of life questionnaires, cosmetic appearance after breast-conserving surgery, arm swelling lymphedema evaluations, and cost analysis of treatments. Overall survival and breast cancer-specific survival will also be tracked for up to five years to understand long-term outcomes.
CONDITIONS
Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy
T
Tabassum Wadasadawala, MD, DNB Radiotherapy
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Dr. Tabassum Wadasadawala
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to completion of chemotherapy and radiotherapy (variable duration)
Participants receive adjuvant chemotherapy and radiotherapy either sequentially or concurrently as part of their breast cancer treatment.
Duration - Up to 5 years after treatment
Participants are monitored for disease-free survival, quality of life, cosmesis, lymphedema, and survival outcomes after completing treatment.
Visits every 6 months for 5 years, with some assessments annually
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tabassum Wadasadawala, Akanksha Anup, Johnny Carlton...
https://pubmed.ncbi.nlm.nih.gov/37113709/Dr. Tabassum Wadasadawala
Lead Sponsor